Is Inovio Pharmaceuticals Inc (INO) overvalued? · rev $65.3K
Inovio Pharmaceuticals Inc (INO) is a biotechnology company listed on US.
This page asks whether Inovio Pharmaceuticals Inc (INO) looks expensive on cached numbers — not a short thesis.
Latest reported INO revenue for 2025-12-31 was $65.3K. Net income was -$84.9M. Revenue was down 70.0% from 2024-12-31 to 2025-12-31. INO currently screens at market cap $88.0M.
INO currently screens at market cap $88.0M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next INO 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the INO stock page for the full model, not this heading.
Not investment advice.